Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients ; volume:73 ; number:9 ; day:5 ; month:7 ; year:2024 ; pages:1-7 ; date:9.2024
Cancer immunology immunotherapy ; 73, Heft 9 (5.7.2024), 1-7, 9.2024

Creator
Gawaz, A.
Wolff, I.
Nanz, L.
Flatz, L.
Forschner, A.
Contributor
SpringerLink (Online service)

DOI
10.1007/s00262-024-03750-1
URN
urn:nbn:de:101:1-2410310802430.401579870944
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:23 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Gawaz, A.
  • Wolff, I.
  • Nanz, L.
  • Flatz, L.
  • Forschner, A.
  • SpringerLink (Online service)

Other Objects (12)

Preclinical comparison of prolgolimab, pembrolizumab and nivolumab

Preclinical comparison of prolgolimab, pembrolizumab and nivolumab

Autoimmune Nebenwirkungen von Nivolumab, Ipilimumab und Pembrolizumab : Chancen und Risiken der Therapie mit Checkpoint-Inhibitoren

Hochschulschrift

Autoimmune Nebenwirkungen von Nivolumab, Ipilimumab und Pembrolizumab : Chancen und Risiken der Therapie mit Checkpoint-Inhibitoren

Author Correction: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab

Author Correction: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Nivolumab (Melanom, adjuvant) : Addendum zum Auftrag A21-39

Nivolumab (Melanom, adjuvant) : Addendum zum Auftrag A21-39

Nivolumab a New Standard of Care in Adjuvant Settings in Esophageal and Gastroesophageal Junctional Cancer Patients

Nivolumab a New Standard of Care in Adjuvant Settings in Esophageal and Gastroesophageal Junctional Cancer Patients

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA

Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma

Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma

Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland

Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland

Pembrolizumab (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung

Pembrolizumab (NSCLC, adjuvant) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung

Pembrolizumab (Melanom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung

Pembrolizumab (Melanom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung

Related objects